Arcus Biosciences, Inc.
NYSE:RCUSBiotechnology
-$0.09 today
- Market cap
- $2.27B
- Beta
- 0.84
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$2.94
Volume 1.97M
Average 1.17M
RCUS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Arcus Biosciences, Inc.NYSE: RCUS
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $3M rose 50.0% year over year, ahead of the +0.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 50.0% from the prior quarter. Over 3 fiscal years it compounded at +18.6% a year.
Context
- Depreciation & amortization amounted to 4.0% of revenue in FY2025, up 0.2 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +50.0% holds above the trailing-twelve-month pace of +0.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 10M USD
- Year-over-year change
- +0.0%
- 4-year CAGR
- +25.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10M | +0.0% |
| FY2024 | 2024-12-31 | 10M | +25.0% |
| FY2023 | 2023-12-31 | 8M | +33.3% |
| FY2022 | 2022-12-31 | 6M | +50.0% |
| FY2021 | 2021-12-31 | 4M | — |
Depreciation & Amortization vs competitors
How RCUS compares with its peers on the latest reported figures
- RCUS's LTM Jun 2026 depreciation & amortization of $10M is the 4th largest of the 9 companies compared; the peer median is $4.94M.
- Its year-over-year change of +0.0% is the 5th highest of 9, against a peer median of -1.0%.
- Depreciation & amortization amounts to 8.5% of revenue for RCUS, versus a peer median of 8.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $22.24M | +1.2% | +16.4% | 14.3% | |
| LTM Sep 2026 | $16.54M | +4.6% | -5.3% | 9.1% | |
| LTM Jun 2026 | $13.14M | +17.5% | +12.6% | 364.7% | |
| LTM Jun 2026 | $10M | +0.0% | +18.6% | 8.5% | |
| LTM Mar 2026 | $5.26M | -5.7% | -15.4% | 8.0% | |
| LTM Mar 2026 | $4.63M | +20.2% | +27.0% | 8.9% | |
| LTM Jun 2026 | $4.18M | -7.0% | -8.0% | — | |
| LTM Jun 2026 | $1.69M | -9.0% | -25.2% | 0.4% | |
| LTM Jun 2026 | $468K | -3.1% | +21.7% | 0.7% | |
| Peer median (excluding RCUS) | $4.94M | -1.0% | +3.7% | 8.9% | |
Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 52.83M | (267M) | (307M) | (283M) | (353M) |
| Depreciation & Amortization | 4M | 6M | 8M | 10M | 10M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 55M | 65M | 73M | 76M | 60M |
| Change in Working Capital | (375.62M) | 623M | (71M) | 22M | (194M) |
| Accounts Receivables | (17.05M) | 704M | 15M | 28M | 9M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.77M) | 8M | (1M) | 3M | 24M |
| Other Working Capital | (353.8M) | (89M) | (85M) | (9M) | (227M) |
| Other Non-Cash Items | 7.62M | 11M | (9M) | 5M | (5M) |
| Operating Cash Flow | (256.17M) | 438M | (306M) | (170M) | (482M) |
| Capital Expenditures | (26.08M) | (6M) | (24M) | (6M) | (2M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (718.87M) | (1.24B) | (788M) | (1.04B) | (1.08B) |
| Sales of Investments | 741.08M | 837M | 1.01B | 965M | 1.14B |
| Other Investing Activities | 0 | (3M) | 0 | 0 | 0 |
| Investing Cash Flow | (3.87M) | (413M) | 194M | (84M) | 66M |
| Debt Repayment | 5M | 0 | 0 | 47M | 49M |
| Common Stock Issued | 232.35M | 23M | 25M | 228M | 439M |
| Common Stock Repurchased | (6K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 10M | 8M | 2M | 0 |
| Financing Cash Flow | 237.34M | 33M | 33M | 277M | 488M |
| Effect of Forex Changes | (2.8M) | 0 | 0 | 0 | 0 |
| Net Change in Cash | (25.5M) | 58M | (79M) | 23M | 72M |
| Free Cash Flow | (282.25M) | 432M | (330M) | (176M) | (484M) |
Arcus Biosciences, Inc.
NYSE:RCUS
Intrinsic Alpha fair value
Locked
Current Price
$15.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.